Treatments based on Sigilon Therapeutics' Afibromer technology platform include cell implants that act as responsive "living therapeutics," providing more natural control for diseases that are currently treated with intermittent injection or infusion.

Initial areas of focus include hematologic, enzyme deficiency, endocrine and metabolic disorders.